Erin Magennis Healy combines industry knowledge with technical experience to provide comprehensive legal representation to clients operating in the healthcare and life sciences industries, as well as strategic advice to private equity firms and other investors seeking to evaluate risks in a complicated regulatory landscape. Erin is well-versed on federal and state compliance matters, including fraud and abuse laws, anti-kickback and self-referral laws, FDA regulations and limitations on the use and disclosure of personal information. In addition to helping clients develop and implement comprehensive compliance and training programs, Erin serves as deal counsel on a wide range of mission-critical transactions including mergers and acquisitions, licensing agreements, research agreements, manufacturing, supply and distribution agreements, and other strategic commercial arrangements. She also supports clients on day-to-day legal matters, offering creative and practical advice to help clients achieve commercial goals.

Erin previously managed clinical trials at top academic medical centers in New York City and contributed to several published, peer-reviewed articles on surgical and clinical outcomes, affording her substantial experience developing clinical trial agreements and a strong background in federal and institutional research regulations.